{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:38:59Z","timestamp":1787002739851,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011624","name":"Marshfield Clinic Research Foundation","doi-asserted-by":"publisher","award":["252840-00"],"award-info":[{"award-number":["252840-00"]}],"id":[{"id":"10.13039\/100011624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011624","name":"Marshfield Clinic Research Foundation","doi-asserted-by":"publisher","award":["284010-00"],"award-info":[{"award-number":["284010-00"]}],"id":[{"id":"10.13039\/100011624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011624","name":"Marshfield Clinic Research Foundation","doi-asserted-by":"publisher","award":["284000-00"],"award-info":[{"award-number":["284000-00"]}],"id":[{"id":"10.13039\/100011624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA-125387"],"award-info":[{"award-number":["CA-125387"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA-022443"],"award-info":[{"award-number":["CA-022443"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The orphan nuclear receptor NR2E3 has emerged as a potential tumor suppressor, yet its precise mechanisms in tumorigenesis require further investigation. Here, we demonstrate that the full-length protein isoform of NR2E3 instead of its short isoform activates wild-type p53 and is capable of rescuing certain p53 mutations in various cancer cell lines. Importantly, we observe a higher frequency of NR2E3 mutations in three solid tumors compared to the reference population, highlighting its potential significance in tumorigenesis. Specifically, we identify a cancer-associated NR2E3\n                    <jats:sup>R97H<\/jats:sup>\n                    mutation, which not only fails to activate p53 but also impedes NR2E3\n                    <jats:sup>WT<\/jats:sup>\n                    -mediated p53 acetylation. Moreover, we show that the small-molecule agonist of NR2E3, 11a, penetrates tumor mass of uterine cancer patients and increases p53 activation. Additionally, both NR2E3 and 11a exhibit similar multifaceted anti-cancer properties, underscoring NR2E3 as a novel molecular vulnerability in cancer cells. We further explore drug repurposing screens of FDA-approved anti-cancer drugs to develop NR2E3-targeted combinatorial treatments, such as the 11a-Romidepsin combination in HeLa cells. The underlying molecular mechanisms of these drug synergies include the activation of p53 pathway and inhibition of oncogenic pathway like MYC. Overall, our findings suggest that NR2E3 holds promise as a therapeutic target for cancer treatment, offering new avenues for effective anti-cancer strategies.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-07337-1","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:13:03Z","timestamp":1736809983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Orphan nuclear receptor NR2E3 is a new molecular vulnerability in solid tumors by activating p53"],"prefix":"10.1038","volume":"16","author":[{"given":"Yidan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd G.","family":"Kroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-622X","authenticated-orcid":false,"given":"Zhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"7337_CR1","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1073\/pnas.96.9.4814","volume":"96","author":"M Kobayashi","year":"1999","unstructured":"Kobayashi M, Takezawa S, Hara K, Yu RT, Umesono Y, Agata K, et al. Identification of a photoreceptor cell-specific nuclear receptor. Proc Natl Acad Sci USA. 1999;96:4814\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7337_CR2","doi-asserted-by":"publisher","first-page":"15149","DOI":"10.1073\/pnas.96.26.15149","volume":"96","author":"F Chen","year":"1999","unstructured":"Chen F, Figueroa DJ, Marmorstein AD, Zhang Q, Petrukhin K, Caskey CT, et al. Retina-specific nuclear receptor: a potential regulator of cellular retinaldehyde-binding protein expressed in retinal pigment epithelium and Muller glial cells. Proc Natl Acad Sci USA. 1999;96:15149\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7337_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000015635","volume":"89","author":"ND Rendtorff","year":"2000","unstructured":"Rendtorff ND, Vissing H, Tumer Z, Silahtaroglu A, Tommerup N. Assignment of the NR2E3 gene to mouse chromosome 9 and to human chromosome 15q22.33->q23. Cytogenet Cell Genet. 2000;89:279\u201380.","journal-title":"Cytogenet Cell Genet"},{"key":"7337_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.ophtha.2005.07.002","volume":"112","author":"T Hayashi","year":"2005","unstructured":"Hayashi T, Gekka T, Goto-Omoto S, Takeuchi T, Kubo A, Kitahara K. Novel NR2E3 mutations (R104Q, R334G) associated with a mild form of enhanced S-cone syndrome demonstrate compound heterozygosity. Ophthalmology. 2005;112:2115.","journal-title":"Ophthalmology"},{"key":"7337_CR5","doi-asserted-by":"publisher","first-page":"e74359","DOI":"10.1371\/journal.pone.0074359","volume":"8","author":"MH Tan","year":"2013","unstructured":"Tan MH, Zhou XE, Soon FF, Li X, Li J, Yong EL, et al. The crystal structure of the orphan nuclear receptor NR2E3\/PNR ligand binding domain reveals a dimeric auto-repressed conformation. PLoS ONE. 2013;8:e74359.","journal-title":"PLoS ONE"},{"key":"7337_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1523\/JNEUROSCI.3571-04.2005","volume":"25","author":"J Chen","year":"2005","unstructured":"Chen J, Rattner A, Nathans J. The rod photoreceptor-specific nuclear receptor Nr2e3 represses transcription of multiple cone-specific genes. J Neurosci. 2005;25:118\u201329.","journal-title":"J Neurosci"},{"key":"7337_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/hmg\/ddi070","volume":"14","author":"GH Peng","year":"2005","unstructured":"Peng GH, Ahmad O, Ahmad F, Liu J, Chen S. The photoreceptor-specific nuclear receptor Nr2e3 interacts with Crx and exerts opposing effects on the transcription of rod versus cone genes. Hum Mol Genet. 2005;14:747\u201364.","journal-title":"Hum Mol Genet"},{"key":"7337_CR8","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1016\/j.bmcl.2006.07.056","volume":"16","author":"SE Wolkenberg","year":"2006","unstructured":"Wolkenberg SE, Zhao Z, Kapitskaya M, Webber AL, Petrukhin K, Tang YS, et al. Identification of potent agonists of photoreceptor-specific nuclear receptor (NR2E3) and preparation of a radioligand. Bioorg Med Chem Lett. 2006;16:5001\u20134.","journal-title":"Bioorg Med Chem Lett"},{"key":"7337_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/72777","volume":"24","author":"NB Haider","year":"2000","unstructured":"Haider NB, Jacobson SG, Cideciyan AV, Swiderski R, Streb LM, Searby C, et al. Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet. 2000;24:127\u201331.","journal-title":"Nat Genet"},{"key":"7337_CR10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1093\/hmg\/10.16.1619","volume":"10","author":"NB Haider","year":"2001","unstructured":"Haider NB, Naggert JK, Nishina PM. Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7\/rd7 mice. Hum Mol Genet. 2001;10:1619\u201326.","journal-title":"Hum Mol Genet"},{"key":"7337_CR11","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/0042-6989(95)98727-Q","volume":"35","author":"DC Hood","year":"1995","unstructured":"Hood DC, Cideciyan AV, Roman AJ, Jacobson SG. Enhanced S cone syndrome: evidence for an abnormally large number of S cones. Vis Res. 1995;35:1473\u201381.","journal-title":"Vis Res"},{"key":"7337_CR12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/hmg\/ddh198","volume":"13","author":"SG Jacobson","year":"2004","unstructured":"Jacobson SG, Sumaroka A, Aleman TS, Cideciyan AV, Schwartz SB, Roman AJ, et al. Nuclear receptor NR2E3 gene mutations distort human retinal laminar architecture and cause an unusual degeneration. Hum Mol Genet. 2004;13:1893\u2013902.","journal-title":"Hum Mol Genet"},{"key":"7337_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98271-7","volume":"11","author":"G Venturini","year":"2021","unstructured":"Venturini G, Kokona D, Steiner BL, Bulla EG, Jovanovic J, Zinkernagel MS, et al. In vivo analysis of onset and progression of retinal degeneration in the Nr2e3(rd7\/rd7) mouse model of enhanced S-cone sensitivity syndrome. Sci Rep. 2021;11:19032.","journal-title":"Sci Rep"},{"key":"7337_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9:749\u201358.","journal-title":"Nat Rev Cancer"},{"key":"7337_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307\u201310.","journal-title":"Nature"},{"key":"7337_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2017.171","volume":"25","author":"AM Kaiser","year":"2018","unstructured":"Kaiser AM, Attardi LD. Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 2018;25:93\u2013103.","journal-title":"Cell Death Differ"},{"key":"7337_CR17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","volume":"137","author":"JP Kruse","year":"2009","unstructured":"Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609\u201322.","journal-title":"Cell"},{"key":"7337_CR18","first-page":"6788","volume":"60","author":"A Sigal","year":"2000","unstructured":"Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788\u201393.","journal-title":"Cancer Res"},{"key":"7337_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","volume":"63","author":"M Scheffner","year":"1990","unstructured":"Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129\u201336.","journal-title":"Cell"},{"key":"7337_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1128\/MCB.05513-11","volume":"32","author":"Z Wen","year":"2012","unstructured":"Wen Z, Pyeon D, Wang Y, Lambert P, Xu W, Ahlquist P. Orphan nuclear receptor PNR\/NR2E3 stimulates p53 functions by enhancing p53 acetylation. Mol Cell Biol. 2012;32:26\u201335.","journal-title":"Mol Cell Biol"},{"key":"7337_CR21","doi-asserted-by":"publisher","first-page":"e75198","DOI":"10.1371\/journal.pone.0075198","volume":"8","author":"Z Zhao","year":"2013","unstructured":"Zhao Z, Wang L, Wen Z, Ayaz-Guner S, Wang Y, Ahlquist P, et al. Systematic analyses of the cytotoxic effects of compound 11a, a putative synthetic agonist of photoreceptor-specific nuclear receptor (PNR), in cancer cell lines. PLoS ONE. 2013;8:e75198.","journal-title":"PLoS ONE"},{"key":"7337_CR22","doi-asserted-by":"publisher","first-page":"8335","DOI":"10.1096\/fj.201801881RR","volume":"33","author":"T Khanal","year":"2019","unstructured":"Khanal T, Leung YK, Jiang W, Timchenko N, Ho SM, Kim K. NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. Faseb J. 2019;33:8335\u201348.","journal-title":"Faseb J"},{"key":"7337_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/emmm.201100187","volume":"4","author":"YY Park","year":"2012","unstructured":"Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, et al. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med. 2012;4:52\u201367.","journal-title":"EMBO Mol Med"},{"key":"7337_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11106-2","volume":"7","author":"T Khanal","year":"2017","unstructured":"Khanal T, Choi K, Leung YK, Wang J, Kim D, Janakiram V, et al. Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Sci Rep. 2017;7:10662.","journal-title":"Sci Rep"},{"key":"7337_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.tips.2013.05.004","volume":"34","author":"GN Chan","year":"2013","unstructured":"Chan GN, Hoque MT, Bendayan R. Role of nuclear receptors in the regulation of drug transporters in the brain. Trends Pharm Sci. 2013;34:361\u201372.","journal-title":"Trends Pharm Sci"},{"key":"7337_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jmb.2010.03.005","volume":"398","author":"C Li","year":"2010","unstructured":"Li C, Pazgier M, Li C, Yuan W, Liu M, Wei G, et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2\/MDMX interactions. J Mol Biol. 2010;398:200\u201313.","journal-title":"J Mol Biol"},{"key":"7337_CR27","doi-asserted-by":"publisher","first-page":"22804","DOI":"10.1074\/jbc.M700961200","volume":"282","author":"CL Brooks","year":"2007","unstructured":"Brooks CL, Li M, Gu W. Mechanistic studies of MDM2-mediated ubiquitination in p53 regulation. J Biol Chem. 2007;282:22804\u201315.","journal-title":"J Biol Chem"},{"key":"7337_CR28","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.272.21.13548","volume":"272","author":"S Kumar","year":"1997","unstructured":"Kumar S, Kao WH, Howley PM. Physical interaction between specific E2 and Hect E3 enzymes determines functional cooperativity. J Biol Chem. 1997;272:13548\u201354.","journal-title":"J Biol Chem"},{"key":"7337_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12513","volume":"7","author":"JH Park","year":"2016","unstructured":"Park JH, Yang SW, Park JM, Ka SH, Kim JH, Kong YY, et al. Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Nat Commun. 2016;7:12513.","journal-title":"Nat Commun"},{"key":"7337_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov. 2019;18:219\u201334.","journal-title":"Nat Rev Drug Discov"},{"key":"7337_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.exer.2008.04.006","volume":"87","author":"AL Webber","year":"2008","unstructured":"Webber AL, Hodor P, Thut CJ, Vogt TF, Zhang T, Holder DJ, et al. Dual role of Nr2e3 in photoreceptor development and maintenance. Exp Eye Res. 2008;87:35\u201348.","journal-title":"Exp Eye Res"},{"key":"7337_CR32","first-page":"2174","volume":"15","author":"A Kanda","year":"2009","unstructured":"Kanda A, Swaroop A. A comprehensive analysis of sequence variants and putative disease-causing mutations in photoreceptor-specific nuclear receptor NR2E3. Mol Vis. 2009;15:2174\u201384.","journal-title":"Mol Vis"},{"key":"7337_CR33","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gkab418","volume":"49","author":"C Li","year":"2021","unstructured":"Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic acids Res. 2021;49:W242\u2013W246.","journal-title":"Nucleic acids Res"},{"key":"7337_CR34","doi-asserted-by":"publisher","first-page":"e173892","DOI":"10.1172\/JCI173892","volume":"134","author":"NK Mullin","year":"2024","unstructured":"Mullin NK, Bohrer LR, Voigt AP, Lozano LP, Wright AT, Bonilha VL, Mullins RF, Stone EM, Tucker BA. NR2E3 loss disrupts photoreceptor cell maturation and fate in human organoid models of retinal development. J Clin Invest. 2024;134:e173892.","journal-title":"J Clin Invest"},{"key":"7337_CR35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","volume":"23","author":"A Sajid","year":"2023","unstructured":"Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 2023;23:762\u201379.","journal-title":"Nat Rev Cancer"},{"key":"7337_CR36","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/jcb.25496","volume":"117","author":"V Syed","year":"2016","unstructured":"Syed V. TGF-beta signaling in cancer. J Cell Biochem. 2016;117:1279\u201387.","journal-title":"J Cell Biochem"},{"key":"7337_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14114-z","volume":"12","author":"E Flietner","year":"2022","unstructured":"Flietner E, Wen Z, Rajagopalan A, Jung O, Watkins L, Wiesner J, et al. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model. Sci Rep. 2022;12:10616.","journal-title":"Sci Rep"},{"key":"7337_CR38","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/cncr.32138","volume":"125","author":"SL Gaillard","year":"2019","unstructured":"Gaillard SL, Zahurak M, Sharma A, Durham JN, Reiss KA, Sartorius-Mergenthaler S, et al. A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer. 2019;125:2837\u201345.","journal-title":"Cancer"},{"key":"7337_CR39","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u2013W743.","journal-title":"Nucleic Acids Res"},{"key":"7337_CR40","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1167\/iovs.06-1147","volume":"48","author":"V Poulaki","year":"2007","unstructured":"Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, et al. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007;48:4706\u201319.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7337_CR41","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic. Nat Rev Cancer. 2024;24:192\u2013215.","journal-title":"Nat Rev Cancer"},{"key":"7337_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"C Kandoth","year":"2013","unstructured":"Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67\u201373.","journal-title":"Nature"},{"key":"7337_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2020007156","volume":"137","author":"Z Wen","year":"2021","unstructured":"Wen Z, Rajagopalan A, Flietner ED, Yun G, Chesi M, Furumo Q, et al. Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. Blood. 2021;137:61\u201374.","journal-title":"Blood"},{"key":"7337_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.trecan.2020.04.011","volume":"6","author":"E Wang","year":"2020","unstructured":"Wang E, Aifantis I. RNA splicing and cancer. Trends Cancer. 2020;6:631\u201344.","journal-title":"Trends Cancer"},{"key":"7337_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04031-w","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Huang M, Liu X, Huang Y, Liu C, Zhu J, et al. Alternative splicing of mRNA in colorectal cancer: new strategies for tumor diagnosis and treatment. Cell Death Dis. 2021;12:752.","journal-title":"Cell Death Dis"},{"key":"7337_CR46","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/cdd.2016.91","volume":"23","author":"MP Paronetto","year":"2016","unstructured":"Paronetto MP, Passacantilli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell Death Differ. 2016;23:1919\u201329.","journal-title":"Cell Death Differ"},{"key":"7337_CR47","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/mt.2012.194","volume":"20","author":"S Yla-Herttuala","year":"2012","unstructured":"Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20:1831\u20132.","journal-title":"Mol Ther"},{"key":"7337_CR48","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"7337_CR49","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","volume":"103","author":"RL Piekarz","year":"2004","unstructured":"Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636\u201343.","journal-title":"Blood"},{"key":"7337_CR50","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-05-1423","volume":"12","author":"RW Robey","year":"2006","unstructured":"Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res. 2006;12:1547\u201355.","journal-title":"Clin Cancer Res"},{"key":"7337_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin JJ. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharm Ther. 2023;249:108488.","journal-title":"Pharm Ther"},{"key":"7337_CR52","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.3390\/ijms24098389","volume":"24","author":"S Yoon","year":"2023","unstructured":"Yoon S, Kim HS. First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations. Int J Mol Sci. 2023;24:8389.","journal-title":"Int J Mol Sci"},{"key":"7337_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jamadermatol.2019.3353","volume":"156","author":"KG Paulson","year":"2020","unstructured":"Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol. 2020;156:57\u201364.","journal-title":"JAMA Dermatol"},{"key":"7337_CR54","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021013539","volume":"138","author":"O Landgren","year":"2021","unstructured":"Landgren O, Kazandjian D. Diagnosed with myeloma before age 40. Blood. 2021;138:2601\u20132.","journal-title":"Blood"},{"key":"7337_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer Facts & Figures 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07337-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T23:13:07Z","timestamp":1736809987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7337"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07337-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The appendix of \u201cSamples of Unlinked Fresh Tissue Excess\u201d to the approved IRB protocol was approved by the Institutional Review Board of Marshfield Clinic Research Institute in September 2023. The IRB protocol number is IRB-21-88 with MCR Code WEN10221. Three samples were collected between November 2023 and June 2024 with Patient consent form waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate statement"}}],"article-number":"15"}}